Cargando…
Simvastatin prevents and reverses depigmentation in a mouse model of vitiligo
Vitiligo is a common autoimmune disease of the skin that results in disfiguring white spots. There are no FDA-approved treatments, and current treatments are time-consuming, expensive, and have low efficacy. We sought to identify new treatments for vitiligo, and first considered repurposed medicatio...
Autores principales: | Agarwal, Priti, Rashighi, Mehdi, Essien, Kingsley I., Richmond, Jillian M., Randall, Louise, Pazoki-Toroudi, Hamidreza, Hunter, Christopher A., Harris, John E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4366328/ https://www.ncbi.nlm.nih.gov/pubmed/25521459 http://dx.doi.org/10.1038/jid.2014.529 |
Ejemplares similares
-
Proton Pump Inhibitor Induced Depigmentation in Vitiligo
por: Holla, Anantha Prasad, et al.
Publicado: (2011) -
ATP-dependent potassium channels are implicated in simvastatin pretreatment-induced inhibition of apoptotic cell death after renal ischemia/reperfusion injury
por: Dowlatshahi, Kamran, et al.
Publicado: (2015) -
A mouse model of vitiligo with focused epidermal depigmentation requires IFN-γ for autoreactive CD8(+) T cell accumulation in the skin
por: Harris, John E., et al.
Publicado: (2012) -
CCL22 to activate Treg migration and suppress depigmentation in vitiligo
por: Eby, Jonathan M., et al.
Publicado: (2015) -
Psychosocial and quality-of-life factors associated with depigmentation therapy for vitiligo
por: Cadmus, Simi D., et al.
Publicado: (2023)